Cardinal Health is one of America's largest healthcare distributors. It moves branded and generic medicines from drug manufacturers to pharmacies, hospitals, and doctor offices. It also makes and distributes medical products like gloves, syringes, and surgical gowns under its own brand name. On top of that, it runs nuclear pharmacies that prepare radioactive medicines used in medical scans, delivers supplies to patients at home, and now manages physician practices through a growing set of specialty clinics. The company earns money on every transaction: each time a drug ships, each time a medical product moves through the supply chain, and each time a physician practice uses Cardinal's management services. The diagram below traces where the money goes.
How Cardinal Health Makes Money
flowchart LR
A["Pharmaceutical Manufacturers
and Suppliers"] -->|"Products
37% from top 5"| B["Pharma Distribution
and Specialty Services"]
C["Medical Device
Manufacturers"] -->|"Products
for resale"| D["GMPD Segment
Branded and National"]
B -->|"$222.6B Revenue
3.7% margin"| E["Customer Base
30% CVS Health
43% top 5 customers"]
D -->|"Higher margin
products"| E
F["At-Home Solutions
and Nuclear Pharmacy"] -->|"Specialty services"| E
E -->|"Retail pharmacies
Hospitals
Healthcare systems"| G["Operating Cash Flow
$2.4B
Free Cash Flow $1.9B"]
G -->|"Acquisitions
$6.5B in 2025"| H["MSO Platforms
and Strategic Assets"]
H -->|"Managed services
to physician practices"| E
B -->|"Generic pharma
margins peak
at launch"| G
Five years of financial data tell a story of a company getting bigger but thinner at the top, then trying to fix that by moving into higher-margin businesses. Revenue grew from $162.5 billion in 2021 to a peak of $226.8 billion in 2024 before slipping back to $222.6 billion in 2025, mainly because a major contract with OptumRx expired. That one customer had been generating 17 percent of total revenue. Losing it hurt. But the bigger structural issue is gross margin, which measures how much money is left after paying for the products themselves.
What gross margin actually tells you
Gross margin is the share of each dollar of revenue left over after paying for the goods sold. A distributor moving billions of dollars of medicine keeps only a small slice of each dollar because it is passing most of the price straight to the supplier. That small slice has to cover everything else: staff, buildings, technology, debt, and profit.
Gross Margin Rate (%), 2021 to 2025
Gross margin fell four years in a row before recovering in 2025. The 2025 recovery was driven by specialty pharmaceutical products and new physician practice acquisitions, not a reversal of the underlying distribution squeeze.
The gross margin rate dropped from 4.17 percent in 2021 to 3.27 percent in 2024. That is a small number getting smaller. In 2025 it recovered to 3.67 percent, and management credits the new specialty clinic acquisitions and stronger branded pharmaceutical sales for that improvement. Free cash flow, which is the cash left after paying for maintenance and equipment, followed a similar pattern: $2.0 billion in 2021, rising to $3.3 billion in 2024, then dropping back to $1.9 billion in 2025 as the company spent heavily on acquisitions and absorbed the loss of the OptumRx revenue.
$5.3B
Cash spent on acquisitions in fiscal 2025 alone, funding a major push into specialty physician practice management
2024
milestone
The Specialty Pivot
Between March 2024 and May 2025, Cardinal Health spent roughly $7.2 billion acquiring Specialty Networks, Integrated Oncology Network, GI Alliance, Advanced Diabetes Supply, and Urology America. These deals moved the company from pure distribution into running physician practices in oncology, gastroenterology, urology, and diabetes care. The strategy is to earn higher margins by owning more of the care pathway, not just shipping products through it.
The debt picture changed sharply because of this spending spree. Net debt moved from a net cash position of $0.5 billion in 2024 to net debt of $4.1 billion in 2025. The company issued $2.9 billion of new bonds in November 2024 and drew $800 million from a new term loan to fund the GI Alliance and Advanced Diabetes Supply deals. Total long-term obligations stood at $8.5 billion as of June 30, 2025. That is a meaningful shift for a business that had been nearly debt-free just twelve months earlier.
Then there is the opioid settlement, which runs in the background of every financial discussion. Cardinal Health agreed to pay $6.4 billion over 18 years as part of a broader $26 billion national settlement. At June 30, 2025, it still had $4.9 billion accrued and sitting on its balance sheet as a future obligation. In fiscal 2025 alone it paid $798 million toward that liability. Those payments continue through 2038.
$4.9B
Opioid settlement still owed as of June 30, 2025, with payments continuing through 2038 alongside new acquisition debt
Four specific risks stand out from the filings. First, the Department of Justice is investigating Cardinal Health for possible healthcare fraud violations related to a 2022 acquisition. If found in violation, the company could lose access to Medicare and Medicaid programs. That would be catastrophic for a healthcare distributor of this size. Second, the FDA issued a warning letter in April 2024 about plastic syringes from a Chinese supplier that lacked proper clearance. If Cardinal cannot fix supplier compliance issues, it may have to recall products or stop distributing them entirely. Third, regulators are restricting ethylene oxide, a chemical used to sterilize medical products. Cardinal has already been sued over emissions from this chemical, and no clear industry alternative exists yet. Fourth, CVS Health accounts for 30 percent of fiscal 2025 revenue. One customer. Thirty percent. If that relationship changes, the financial impact would be immediate and severe.
What a management services organization does
A management services organization, or MSO, handles the business side of running a doctor's practice: billing, purchasing, staffing support, and technology. The doctors still make medical decisions. The MSO takes a fee for handling everything else. This model can generate higher margins than simply shipping medicines because it involves ongoing services, not just moving boxes.
Cardinal Health is betting that running physician practices through its MSO platforms will produce better margins than distribution alone. The GI Alliance acquisition alone cost $2.8 billion and covers more than 900 physicians across 345 locations. The Integrated Oncology Network adds over 100 providers across 50 sites. These are real businesses, but integrating them while managing $4.9 billion in opioid obligations, $8.5 billion in total long-term debt, and the ongoing compliance pressure from federal regulators is a complicated balancing act.
The expiration of the OptumRx contracts in June 2024 removed 17 percent of consolidated revenue in a single step. The company replaced some of that volume with new customers, but the working capital unwind from losing OptumRx also reduced operating cash flow in fiscal 2025. A single contract expiration reshaping the entire year's financials shows just how concentrated the revenue base can be.
30%
CVS Health share of 2025 revenue
13%
Next 4 largest customers combined
CVS Health alone represents more than twice the revenue contribution of the next four largest customers combined, making it the single most important relationship in the business.
$8.2B
Gross margin in fiscal 2025, up 10% from 2024, driven by specialty pharmaceuticals and MSO acquisitions rather than core distribution improvement
The Bet
Cardinal Health can successfully transform from a low-margin drug distributor into a higher-margin healthcare services company by owning and running physician practices at scale. The MSO acquisitions have to generate enough additional profit to offset the rising interest costs on $8.5 billion in long-term debt, cover $4.9 billion in remaining opioid payments, and replace the margin that has been steadily eroding in the core distribution business. If the MSO platforms underperform, or if integrating hundreds of physician practices proves harder than expected, the company will be carrying a much heavier debt load without the earnings improvement that justified taking it on.
Open question
Cardinal Health has spent over $7 billion in two years to move beyond distribution and into running doctor offices. Gross margin improved in 2025 for the first time in five years. Opioid payments continue through 2038. The DOJ investigation is unresolved. CVS Health represents 30 percent of revenue. Can a company that built its scale by efficiently moving products through a supply chain also build a profitable business managing hundreds of physician practices across multiple specialties, while carrying $8.5 billion in debt and writing annual checks toward a $4.9 billion legal settlement?
Compiled · 10-K · FY2025
Regulatory
The Department of Justice is investigating Cardinal Health for possible violations of healthcare fraud laws related to a 2022 acquisition of a group purchasing organization and rheumatology services company. If Cardinal Health is found to have violated these laws, the company could lose the ability to participate in Medicare and Medicaid programs, which would severely damage its business.
Product Quality & Manufacturing
The FDA issued a warning letter in April 2024 about plastic syringes from a Chinese manufacturer that lacked proper clearance. If Cardinal Health cannot resolve quality and compliance issues with its suppliers, the company may be forced to stop distributing products, recall items, or shut down facilities, disrupting operations and damaging customer relationships.
Environmental & Regulatory
Regulators are restricting the use of ethylene oxide and PFOA chemicals used to sterilize medical products. Cardinal Health has been sued over emissions from these chemicals and may face increased compliance costs, supply shortages of sterilized products, or inability to distribute medical devices if the industry cannot find effective alternatives.
Customer Concentration
CVS Health is Cardinal Health's largest customer, accounting for 30 percent of fiscal 2025 revenue. If CVS reduces purchases, stops paying Cardinal Health, or ends their relationship, Cardinal Health's financial results would be severely harmed.
Supply Chain & Commodities
Cardinal Health's manufacturing businesses depend on oil-based materials, cotton, and other commodities whose prices are volatile. Rising supply chain costs have hurt profits for four consecutive years, and the company has not been able to fully pass price increases to customers due to competition and contract limits.
10-K Item 1A · Risk Factors
